SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

SAN

102.28

+0.55%↑

EI

267.6

+0.79%↑

SHL.DE

50.28

+1.23%↑

FRE

39.6

+0.81%↑

PHIA

23.51

+0.69%↑

Search

Argenx SE

Closed

SectorHealthcare

542.8 0.74

Overview

Share price change

24h

Current

Min

538.8

Max

550.2

Key metrics

By Trading Economics

Income

690M

774M

Sales

165M

738M

P/E

Sector Avg

47.333

73.239

EPS

0.72

Profit margin

104.841

Employees

1,599

EBITDA

126M

89M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-2.07% downside

Dividends

By Dow Jones

Next Earnings

8 May 2025

Market Stats

By TradingEconomics

Market Cap

-2B

34B

Previous open

542.06

Previous close

542.8

News Sentiment

By Acuity

70%

30%

339 / 386 Healthcare

Argenx SE Chart

Past performance is not a reliable indicator of future results.

Related News

31 Mar 2025, 22:45 UTC

Top News

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 Mar 2025, 23:54 UTC

Market Talk

Nikkei May Rise After Monday's Selloff -- Market Talk

31 Mar 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 Mar 2025, 23:15 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Mar 2025, 22:33 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 Mar 2025, 22:28 UTC

Earnings

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 Mar 2025, 22:28 UTC

Earnings

China Vanke Swings to Loss for 2024 >000002.SZ

31 Mar 2025, 21:47 UTC

Top News

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 Mar 2025, 21:44 UTC

Top News

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 Mar 2025, 21:21 UTC

Market Talk

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 Mar 2025, 21:18 UTC

Top News

Copper Is 2025's Hottest Commodity -- Update

31 Mar 2025, 21:09 UTC

Top News

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 Mar 2025, 21:02 UTC

Earnings

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 Mar 2025, 21:01 UTC

Earnings

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 Mar 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31 Mar 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Mar 2025, 20:37 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 Mar 2025, 20:17 UTC

Top News

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 Mar 2025, 20:13 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 Mar 2025, 20:03 UTC

Top News

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 Mar 2025, 19:09 UTC

Market Talk

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 Mar 2025, 18:56 UTC

Market Talk

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 Mar 2025, 18:54 UTC

Market Talk

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 Mar 2025, 18:40 UTC

Market Talk

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 Mar 2025, 18:34 UTC

Market Talk

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 Mar 2025, 18:28 UTC

Market Talk

Gold Climbs to Close Out Quarter -- Market Talk

31 Mar 2025, 18:03 UTC

Top News

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Peer Comparison

Price change

Argenx SE Forecast

Price Target

By TipRanks

-2.07% downside

12 Months Forecast

Average 438.33 EUR  -2.07%

High 545 EUR

Low 223 EUR

Based on 6 Wall Street analysts offering 12 month price targets forArgenx SE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Sentiment

By Acuity

339 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.